Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EHP-101 (VCE-004.8) is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. EHP-101 attenuates adipogenesis and prevents diet-induced obesity.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 25,000 | |||
5 mg | 在庫あり | ¥ 55,000 | |||
10 mg | 在庫あり | ¥ 91,500 | |||
25 mg | 在庫あり | ¥ 150,000 | |||
50 mg | 在庫あり | ¥ 209,500 | |||
100 mg | 在庫あり | ¥ 282,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 60,500 |
説明 | EHP-101 (VCE-004.8) is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. EHP-101 attenuates adipogenesis and prevents diet-induced obesity. |
In vivo | In HFD mice, VCE-004.8 (injection; 20?mg/kg/day; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume, and plasma triglycerides levels. VCE-004.8 can also significantly improve glucose tolerance, reduce leptin levels (a sign of obesity) and increase the levels of adiponectin and glucagon (GLP-1 and GIP) [1]. |
別名 | VCE-004.8 |
分子量 | 433.58 |
分子式 | C28H35NO3 |
CAS No. | 1818428-24-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 49 mg/mL (113.01 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EHP-101 1818428-24-8 Chromatin/Epigenetic DNA Damage/DNA Repair GPCR/G Protein Metabolism PPAR Cannabinoid Receptor HIF/HIF Prolyl-Hydroxylase Peroxisome proliferator-activated receptors VCE-004.8 EHP101 HIF-PH Hypoxia-inducible factors inhibit VCE-?004.8 Inhibitor HIFs EHP 101 VCE-004.8 inhibitor